Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 5.48
OCUL's Cash to Debt is ranked higher than
66% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: 60.65 vs. OCUL: 5.48 )
OCUL' s 10-Year Cash to Debt Range
Min: 1.36   Max: No Debt
Current: 5.48

Equity to Asset 0.78
OCUL's Equity to Asset is ranked higher than
81% of the 922 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. OCUL: 0.78 )
OCUL' s 10-Year Equity to Asset Range
Min: -2.9   Max: 0.78
Current: 0.78

-2.9
0.78
Z-Score: 11.35
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 1/10

vs
industry
vs
history
Operating margin (%) -8601.50
OCUL's Operating margin (%) is ranked higher than
51% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -78.59 vs. OCUL: -8601.50 )
OCUL' s 10-Year Operating margin (%) Range
Min: -136710   Max: -136710
Current: -8601.5

Net-margin (%) -9063.30
OCUL's Net-margin (%) is ranked higher than
51% of the 1013 Companies
in the Global Biotechnology industry.

( Industry Median: -70.38 vs. OCUL: -9063.30 )
OCUL' s 10-Year Net-margin (%) Range
Min: -140930   Max: -140930
Current: -9063.3

ROA (%) -85.16
OCUL's ROA (%) is ranked higher than
55% of the 1239 Companies
in the Global Biotechnology industry.

( Industry Median: -28.51 vs. OCUL: -85.16 )
OCUL' s 10-Year ROA (%) Range
Min: -59.94   Max: -59.94
Current: -85.16

ROC (Joel Greenblatt) (%) -2567.18
OCUL's ROC (Joel Greenblatt) (%) is ranked higher than
61% of the 1212 Companies
in the Global Biotechnology industry.

( Industry Median: -442.83 vs. OCUL: -2567.18 )
OCUL' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -2854.65   Max: -2854.65
Current: -2567.18

» OCUL's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

OCUL Guru Trades in

OCUL Guru Trades in

OCUL Guru Trades in

Q3 2014

OCUL Guru Trades in Q3 2014

RS Investment Management 610,900 sh (New)
» More
» Details

Insider Trades

Latest Guru Trades with OCUL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)



No Guru Trades Found!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 5.80
OCUL's P/B is ranked higher than
75% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 5.76 vs. OCUL: 5.80 )
OCUL' s 10-Year P/B Range
Min: 4.36   Max: 5.91
Current: 5.8

4.36
5.91
P/S 1182.03
OCUL's P/S is ranked higher than
67% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 32.74 vs. OCUL: 1182.03 )
OCUL' s 10-Year P/S Range
Min: 336   Max: 454.75
Current: 1182.03

336
454.75
EV-to-EBIT -13.70
OCUL's EV-to-EBIT is ranked higher than
85% of the 1323 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. OCUL: -13.70 )
OCUL' s 10-Year EV-to-EBIT Range
Min: -9.1   Max: -6
Current: -13.7

-9.1
-6
Current Ratio 24.35
OCUL's Current Ratio is ranked higher than
96% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. OCUL: 24.35 )
OCUL' s 10-Year Current Ratio Range
Min: 5.03   Max: 24.35
Current: 24.35

5.03
24.35
Quick Ratio 24.31
OCUL's Quick Ratio is ranked higher than
97% of the 1228 Companies
in the Global Biotechnology industry.

( Industry Median: 4.53 vs. OCUL: 24.31 )
OCUL' s 10-Year Quick Ratio Range
Min: 5.01   Max: 24.31
Current: 24.31

5.01
24.31

Valuation & Return

vs
industry
vs
history
Earnings Yield (Greenblatt) -7.30
OCUL's Earnings Yield (Greenblatt) is ranked lower than
69% of the 1174 Companies
in the Global Biotechnology industry.

( Industry Median: -6.40 vs. OCUL: -7.30 )
OCUL' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0   Max: 0
Current: -7.3

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Ocular Therapeutix Inc was incorporated under the laws of the state of Delaware on September 12, 2006. The Company is a biopharmaceutical company focused on the development and commercialization of therapies for diseases and conditions of the eye using its proprietary hydrogel platform technology. Its hydrogel is a bioresorbable proprietary formulation of polyethylene glycol, or PEG, which when constituted with water takes on a gelatinous consistency. Its product candidates are OTX-DP and OTX-TP. OTX-DP is in Phase 3 clinical development for post-surgical ocular inflammation and pain. OTX-TP is in Phase 2 clinical development for glaucoma and ocular hypertension. It has licensed from Incept approximately 18 U.S. patents, five U.S. patent applications and foreign counterparts of some of these patents and patent applications. Its competitors include Icon Biosciences, Inc., Allergan, Inc., and among others.
» More Articles for OCUL

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: APD, OCUL, CNMD, OPK, AEGR Aug 04 2014 

More From Other Websites
Story Stocks from Briefing.com Nov 26 2014
Will Ocular Therapeutix (OCUL) Continue to Surge Higher? Nov 26 2014
IPO Stock Watch: Second Sight Medical Sees Strong IPO Nov 19 2014
Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results Nov 12 2014
Ocular Therapeutix Inc Earnings Call scheduled for 8:00 am ET today Nov 12 2014
OCULAR THERAPEUTIX, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Nov 12 2014
Q3 2014 Ocular Therapeutix Inc Earnings Release - 07:00 am ET Nov 12 2014
Ocular Therapeutix™ Reports Third Quarter 2014 Financial Results Nov 12 2014
Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial... Nov 12 2014
Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release... Nov 12 2014
Ocular Therapeutix™ Enrolls First Patients in Phase 2b Clinical Trial for Sustained Release... Nov 12 2014
Ocular Therapeutix™ Announces Top-Line Results from Phase 2 Sustained Release Dexamethasone Trial... Nov 12 2014
Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on... Nov 05 2014
Ocular Therapeutix™ to Report Third Quarter 2014 Financial Results and Provide Business Updates on... Nov 05 2014
Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014 Oct 31 2014
Ocular Therapeutix™ to Participate in Two Investor Conferences in November 2014 Oct 31 2014
Ocular Therapeutix™ to Attend American Academy of Ophthalmology Annual Meeting in Chicago,... Oct 14 2014
Ocular Therapeutix™ Completes Enrollment in Phase 3 Sustained Release Dexamethasone Trials for... Oct 08 2014
Ocular Therapeutix to Present at the 21st Annual NewsMakers in the Biotech Industry Investment... Sep 16 2014
Ocular Therapeutix to Present at Morgan Stanley 2014 Global Healthcare Conference Sep 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK